Skip to main content

Advertisement

Log in

Circulating chemerin decreases in response to a combined strength and endurance training

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Chemerin is an adipokine that may mediate the link between obesity, inflammation, insulin resistance, type 2 diabetes mellitus, and cardiovascular disease. In this study, we examined the association between chemerin and various cardiometabolic risk factors in cross-sectional setting and tested the hypothesis that a 6-month combined exercise program decreases serum chemerin in overweight or obese, non-diabetic individuals. Serum chemerin concentration was measured in a cross-sectional analysis including 98 individuals with a wide range of age and body mass index (BMI). In addition, chemerin was measured in 79 sedentary, overweight or obese, non-diabetic individuals who completed a 6-month combined endurance and resistance exercise program (CEP, n = 51) or served as controls (C, n = 28). Chemerin was significantly associated with total cholesterol (p = 0.04), triglycerides (p < 0.001), fasting insulin (p < 0.001), homeostasis model assessment of insulin resistance (HOMA-IR, p < 0.001), systolic blood pressure (p = 0.04), highly sensitive C-reactive protein (p = 0.03), leucocytes count (p = 0.047), and leptin (p = 0.008) independently of age and BMI. In multiple regression analysis, chemerin was an independent determinant of HOMA-IR. As a result of the 6-month training program, serum chemerin decreased significantly in CEP group (−13.8 ± 13.2 ng/ml, p < 0.001). A significant association between the changes in chemerin and improved HOMA-IR were found even after adjustment for changes in waist circumference. Among non-diabetic individuals serum chemerin was associated with various cardiometabolic risk factors independently of BMI. In addition, the 6-month combined strength and endurance training program led to a significant reduction in circulating chemerin levels in overweight or obese individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. T. Temelkova-Kurktschiev, T. Stefanov, Lifestyle and genetics in obesity and type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 120(1), 1–6 (2012)

    CAS  PubMed  Google Scholar 

  2. P. Hossain, B. Kawar, M. El Nahas, Obesity and diabetes in the developing world—a growing challenge. N. Engl. J. Med. 356(3), 213–215 (2007)

    Article  CAS  PubMed  Google Scholar 

  3. H.E. Lebovitz, M.A. Banerji, Point: visceral adiposity is causally related to insulin resistance. Diabetes Care 28(9), 2322–2325 (2005)

    Article  PubMed  Google Scholar 

  4. E.E. Kershaw, J.S. Flier, Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548–2556 (2004)

    Article  CAS  PubMed  Google Scholar 

  5. M. Bluher, Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 117(6), 241–250 (2009)

    Article  CAS  PubMed  Google Scholar 

  6. G.R. Hajer, T.W. van Haeften, F.L. Visseren, Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur. Heart J. 29(24), 2959–2971 (2008)

    Article  CAS  PubMed  Google Scholar 

  7. K. Bozaoglu, K. Bolton, J. McMillan, P. Zimmet, J. Jowett, G. Collier, K. Walder, D. Segal, Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148(10), 4687–4694 (2007)

    Article  CAS  PubMed  Google Scholar 

  8. K.B. Goralski, T.C. McCarthy, E.A. Hanniman, B.A. Zabel, E.C. Butcher, S.D. Parlee, S. Muruganandan, C.J. Sinal, Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 282(38), 28175–28188 (2007)

    Article  CAS  PubMed  Google Scholar 

  9. M. Takahashi, Y. Takahashi, K. Takahashi, F.N. Zolotaryov, K.S. Hong, R. Kitazawa, K. Iida, Y. Okimura, H. Kaji, S. Kitazawa, M. Kasuga, K. Chihara, Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3–L1 adipocytes. FEBS Lett. 582(5), 573–578 (2008)

    Article  CAS  PubMed  Google Scholar 

  10. H. Sell, J. Laurencikiene, A. Taube, K. Eckardt, A. Cramer, A. Horrighs, P. Arner, J. Eckel, Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 58(12), 2731–2740 (2009)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. M.C. Ernst, M. Issa, K.B. Goralski, C.J. Sinal, Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology 151(5), 1998–2007 (2010)

    Article  CAS  PubMed  Google Scholar 

  12. M. Becker, K. Rabe, C. Lebherz, J. Zugwurst, B. Goke, K.G. Parhofer, M. Lehrke, U.C. Broedl, Expression of human chemerin induces insulin resistance in the skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes 59(11), 2898–2903 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. J. Weigert, M. Neumeier, J. Wanninger, M. Filarsky, S. Bauer, R. Wiest, S. Farkas, M.N. Scherer, A. Schaffler, C. Aslanidis, J. Scholmerich, C. Buechler, Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin. Endocrinol. (Oxf) 72(3), 342–348 (2010)

    Article  CAS  Google Scholar 

  14. K. Bozaoglu, D. Segal, K.A. Shields, N. Cummings, J.E. Curran, A.G. Comuzzie, M.C. Mahaney, D.L. Rainwater, J.L. VandeBerg, J.W. MacCluer, G. Collier, J. Blangero, K. Walder, J.B. Jowett, Chemerin is associated with metabolic syndrome phenotypes in a Mexican–American population. J. Clin. Endocrinol. Metab. 94(8), 3085–3088 (2009)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. R. Chakaroun, M. Raschpichler, N. Kloting, A. Oberbach, G. Flehmig, M. Kern, M.R. Schon, E. Shang, T. Lohmann, M. Dressler, M. Fasshauer, M. Stumvoll, M. Bluher, Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism (2011). doi:10.1016/j.metabol.2011.10.008

  16. T. Sledzinski, J. Korczynska, A. Hallmann, L. Kaska, M. Proczko-Markuszewska, T. Stefaniak, M. Sledzinski, J. Swierczynski, The increase of serum chemerin concentration is mainly associated with the increase of BMI in obese, non-diabetic subjects. J. Endocrinol. Invest. (2012). doi:10.3275/8770

  17. A. Tonjes, M. Fasshauer, J. Kratzsch, M. Stumvoll, M. Bluher, Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One 5(11), e13911 (2010)

    Article  PubMed Central  PubMed  Google Scholar 

  18. M. Yang, G. Yang, J. Dong, Y. Liu, H. Zong, H. Liu, G. Boden, L. Li, Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J. Investig. Med. 58(7), 883–886 (2010)

    CAS  PubMed  Google Scholar 

  19. S.H. Chu, M.K. Lee, K.Y. Ahn, J.A. Im, M.S. Park, D.C. Lee, J.Y. Jeon, J.W. Lee, Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 7(4), e34710 (2012)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. N. Kloting, M. Fasshauer, A. Dietrich, P. Kovacs, M.R. Schon, M. Kern, M. Stumvoll, M. Bluher, Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299(3), E506–E515 (2010)

    Article  PubMed  Google Scholar 

  21. A.A. Roman, S.D. Parlee, C.J. Sinal, Chemerin: a potential endocrine link between obesity and type 2 diabetes. Endocrine 42(2), 243–251 (2012)

    Article  CAS  PubMed  Google Scholar 

  22. D.M. Ouwens, M. Bekaert, B. Lapauw, Y. Van Nieuwenhove, S. Lehr, S. Hartwig, P. Calders, J.M. Kaufman, H. Sell, J. Eckel, J.B. Ruige, Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Arch. Physiol. Biochem. 118(3), 135–138 (2012)

    Article  CAS  PubMed  Google Scholar 

  23. S.N. Blair, J.N. Morris, Healthy hearts–and the universal benefits of being physically active: physical activity and health. Ann. Epidemiol. 19(4), 253–256 (2009)

    Article  PubMed  Google Scholar 

  24. T. Stefanov, A. Vekova, I. Bonova, S. Tzvetkov, D. Kurktschiev, M. Bluher, T. Temelkova-Kurktschiev, Effects of supervised vs non-supervised combined aerobic and resistance exercise programme on cardiometabolic risk factors. Cent. Eur. J. Public Health 21(1), 239–243 (2013)

    Google Scholar 

  25. M. Venojarvi, N. Wasenius, S. Manderoos, O.J. Heinonen, M. Hernelahti, H. Lindholm, J. Surakka, J. Lindstrom, S. Aunola, M. Atalay, J.G. Eriksson, Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. Ann. Med. (2012). doi:10.3109/07853890.2012.727020

  26. B.E. Ainsworth, W.L. Haskell, S.D. Herrmann, N. Meckes, D.R. Bassett Jr., C. Tudor-Locke, J.L. Greer, J. Vezina, M.C. Whitt-Glover, A.S. Leon, Compendium of Physical Activities: a second update of codes and MET values. Med. Sci. Sports Exerc. 43(8), 1575–1581 (2011)

    Article  PubMed  Google Scholar 

  27. V. Noonan, E. Dean, Submaximal exercise testing: clinical application and interpretation. Phys. Ther. 80(8), 782–807 (2000)

    CAS  PubMed  Google Scholar 

  28. C. Foster, A.S. Jackson, M.L. Pollock, M.M. Taylor, J. Hare, S.M. Sennett, J.L. Rod, M. Sarwar, D.H. Schmidt, Generalized equations for predicting functional capacity from treadmill performance. Am. Heart J. 107(6), 1229–1234 (1984)

    Article  CAS  PubMed  Google Scholar 

  29. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7), 412–419 (1985)

    Article  CAS  PubMed  Google Scholar 

  30. P. Zimmet, D. Magliano, Y. Matsuzawa, G. Alberti, J. Shaw, The metabolic syndrome: a global public health problem and a new definition. J. Atheroscler. Thromb. 12(6), 295–300 (2005)

    Article  CAS  PubMed  Google Scholar 

  31. M. Lehrke, A. Becker, M. Greif, R. Stark, R.P. Laubender, F. von Ziegler, C. Lebherz, J. Tittus, M. Reiser, C. Becker, B. Goke, A.W. Leber, K.G. Parhofer, U.C. Broedl, Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur. J. Endocrinol. 161(2), 339–344 (2009)

    Article  CAS  PubMed  Google Scholar 

  32. D. Stejskal, M. Karpisek, Z. Hanulova, M. Svestak, Chemerin is an independent marker of the metabolic syndrome in a Caucasian population–a pilot study. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 152(2), 217–221 (2008)

    Article  CAS  PubMed  Google Scholar 

  33. H.Y. Shin, D.C. Lee, S.H. Chu, J.Y. Jeon, M.K. Lee, J.A. Im, J.W. Lee, Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin. Endocrinol. (Oxf) (2011). doi:10.1111/j.1365-2265.2011.04217.x

  34. B. Dong, W. Ji, Y. Zhang, Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern. Med. 50(10), 1093–1097 (2011)

    Article  CAS  PubMed  Google Scholar 

  35. V. Catalan, J. Gomez-Ambrosi, A. Rodriguez, B. Ramirez, F. Rotellar, V. Valenti, C. Silva, M.J. Gil, J. Salvador, G. Fruhbeck, Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-alpha stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg. Obes. Relat. Dis. (2011). doi:10.1016/j.soard.2011.11.001

  36. S. Bauer, M. Bala, A. Kopp, K. Eisinger, A. Schmid, S. Schneider, M. Neumeier, C. Buechler, Adipocyte chemerin release is induced by insulin without being translated to higher levels in vivo. Eur. J. Clin. Invest. 42(11), 1213–1220 (2012)

    Article  CAS  PubMed  Google Scholar 

  37. B.K. Tan, J. Chen, S. Farhatullah, R. Adya, J. Kaur, D. Heutling, K.C. Lewandowski, J.P. O’Hare, H. Lehnert, H.S. Randeva, Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 58(9), 1971–1977 (2009)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. M.C. Ernst, C.J. Sinal, Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol. Metab. 21(11), 660–667 (2010)

    Article  CAS  PubMed  Google Scholar 

  39. M. Bluher, A. Rudich, N. Kloting, R. Golan, Y. Henkin, E. Rubin, D. Schwarzfuchs, Y. Gepner, M.J. Stampfer, M. Fiedler, J. Thiery, M. Stumvoll, I. Shai, Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care 35(2), 342–349 (2012)

    Article  PubMed Central  PubMed  Google Scholar 

  40. H. Sell, A. Divoux, C. Poitou, A. Basdevant, J.L. Bouillot, P. Bedossa, J. Tordjman, J. Eckel, K. Clement, Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 95(6), 2892–2896 (2010)

    Article  CAS  PubMed  Google Scholar 

  41. C. Ress, A. Tschoner, J. Engl, A. Klaus, H. Tilg, C.F. Ebenbichler, J.R. Patsch, S. Kaser, Effect of bariatric surgery on circulating chemerin levels. Eur. J. Clin. Invest. 40(3), 277–280 (2010)

    Article  CAS  PubMed  Google Scholar 

  42. T.A. Lakka, D.E. Laaksonen, H.M. Lakka, N. Mannikko, L.K. Niskanen, R. Rauramaa, J.T. Salonen, Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome. Med. Sci. Sports Exerc. 35(8), 1279–1286 (2003)

    Article  PubMed  Google Scholar 

  43. P.T. Katzmarzyk, T.S. Church, S.N. Blair, Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch. Intern. Med. 164(10), 1092–1097 (2004)

    Article  PubMed  Google Scholar 

  44. D.C. Lee, X. Sui, T.S. Church, I.M. Lee, S.N. Blair, Associations of cardiorespiratory fitness and obesity with risks of impaired fasting glucose and type 2 diabetes in men. Diabetes Care 32(2), 257–262 (2009)

    Article  PubMed Central  PubMed  Google Scholar 

  45. D. Stensvold, A.E. Tjonna, E.A. Skaug, S. Aspenes, T. Stolen, U. Wisloff, S.A. Slordahl, Strength training versus aerobic interval training to modify risk factors of metabolic syndrome. J. Appl. Physiol. 108(4), 804–810 (2010)

    Article  PubMed  Google Scholar 

  46. C.A. Libardi, G.V. De Souza, C.R. Cavaglieri, V.A. Madruga, M.P. Chacon-Mikahil, Effect of resistance, endurance, and concurrent training on TNF-alpha, IL-6, and CRP. Med. Sci. Sports Exerc. 44(1), 50–56 (2012)

    Article  CAS  PubMed  Google Scholar 

  47. L.A. Bateman, C.A. Slentz, L.H. Willis, A.T. Shields, L.W. Piner, C.W. Bales, J.A. Houmard, W.E. Kraus, Comparison of aerobic versus resistance exercise training effects on metabolic syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise-STRRIDE-AT/RT). Am. J. Cardiol. 108(6), 838–844 (2011)

    Article  PubMed Central  PubMed  Google Scholar 

  48. C.A. Slentz, L.A. Bateman, L.H. Willis, A.T. Shields, C.J. Tanner, L.W. Piner, V.H. Hawk, M.J. Muehlbauer, G.P. Samsa, R.C. Nelson, K.M. Huffman, C.W. Bales, J.A. Houmard, W.E. Kraus, Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT. Am. J. Physiol. Endocrinol. Metab. 301(5), E1033–E1039 (2011)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank all study participants and Daniela Kox, Manuela Prellberg, and Susan Berthold for their technical assistance.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

The authors of the current manuscript declare that all the experiments comply with the current laws of the country in which they were performed (Bulgaria). The study conforms to the principles outlined in the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of the National Sports Academy, Sofia, Bulgaria and all subjects gave their written informed consent prior to participation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tsvetan Stefanov.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stefanov, T., Blüher, M., Vekova, A. et al. Circulating chemerin decreases in response to a combined strength and endurance training. Endocrine 45, 382–391 (2014). https://doi.org/10.1007/s12020-013-0003-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-0003-2

Keywords

Navigation